[뉴욕=뉴스핌]Correspondent Kim Geun-cheol = The European Union (EU) executive committee approved the use of the Corona 19 vaccine jointly developed by AstraZeneca and Oxford University in the UK on the 29th (local time).
Executive Chairman Ursula Ponderrayen said on Twitter that day, “I look forward to providing 400 million doses of vaccine as agreed by this company (AstraZeneca),” said Reuters.
The decision was made quickly, a few hours after the European Medicines Agency (EMA) recommended approval for conditional emergency use. AstraZeneca’s Corona 19 vaccine became the third vaccine to be approved for use by the EU after Pfizer and Modena products.
Previously, EMA reviewed clinical trials of the AstraZeneca Corona 19 vaccine conducted in the UK, Brazil, and South Africa, and recommended approval that the vaccine has been shown to be safe and effective in preventing Corona 19 in people over the age of 18.
The AstraZeneca vaccine requires two doses and the interval is between 4 and 12 weeks, according to the EMA.
However, EMA said that there is not yet sufficient results to determine how effective it is in the age group over 55, and that additional protective measures are expected for these age groups, and it is not clear about the extent of that.
Most of the participants in the AstraZeneca Corona 19 vaccine test consisted of 18 to 55 years old. Due to this, claims have been raised that question the safety and efficacy of vaccination for the elderly.
In particular, the immunization committee under the Robert Koch Institute (RKI), a health agency of the German Ministry of Health, issued an initial recommendation on the previous day, saying, “Astrezeneca vaccine should be vaccinated only for those aged 18-64.”
Meanwhile, World Health Organization (WHO) chief scientist Dr. Sumya Swaminatan said he hopes the AstraZeneca vaccine will be added to the WHO’s urgent use vaccine list within the next two weeks.
 |
| AstraZeneca Corona 19 Vaccine [사진=로이터 뉴스핌] |